FEB 29 - (Washington, D.C.) – U.S. Drug Enforcement Administration (DEA) Acting
Administrator Chuck Rosenberg and the Chief of DEA’s Office of Diversion Control,
Lou Milione hosted a meeting today in Washington with industry leaders representing
the prescription drug supply chain in America. The purpose of their dialogue was to
discuss ways to minimize pharmaceutical diversion while maintaining legitimate
commerce and patient access.
“The pharmaceutical industry has a vital role on the front lines of preventing drug
misuse and abuse across America, as do we, and we plan to work closely with
them,” said Acting Administrator Rosenberg. “Today’s forum helps us all to find
the right balance between providing patients with important prescription medications
and reducing the addictions, overdoses, and crimes that too often result from these
substances falling into the wrong hands.”
“DEA is creating opportunities to interact with these companies about their roles and
responsibilities under the Controlled Substances Act. A clear understanding of each
other’s goals and challenges better equips both of us to fight our country’s prescription
drug abuse epidemic,” said Deputy Assistant Administrator Milione.
At this forum, DEA presented attendees with information on federal laws and regulations
affecting their industry, and provided a forum to ask questions, share their perspectives
and voice concerns about regulatory requirements and current issues.
The abuse of controlled-substance medications is an epidemic in America today.
6.5 million people aged 12 and over abused these drugs in 2014, according to the
Substance Abuse and Mental Health Services Administration’s National Survey on
Drug Use and Health. According to the Centers for Disease Control and Prevention,
in 2013 someone died of an unintentional drug overdose every 13 minutes, and
more than half of those overdoses were attributed to these medications.
.png)
No hay comentarios:
Publicar un comentario